Building Growth Momentum in HealthCare. 30 th Annual J.P. Morgan Healthcare Conference
|
|
- Cody Harrington
- 5 years ago
- Views:
Transcription
1 30 th Annual J.P. Morgan Healthcare Conference Building Growth Momentum in HealthCare Dr. Jörg Reinhardt Chairman of the Board of Management Bayer HealthCare 2012, January 10, San Francisco
2 Disclaimer This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forwardlooking statements or to conform them to future events or developments.
3 HealthCare Leading Positions in Key Markets 2010 sales in million Pharma 10,908m Leading positions in key therapeutic categories Sales Split by Segment 2010 Consumer Care 3,371m Global #2 in OTC-pharmaceuticals Medical Care 1,514m #1 in fluid injection systems, #4 in blood glucose meters 25% 64% 7% 20% 9% Animal Health 1,120m Global #4 HealthCare 16,913m Page 1 J.P. Morgan Healthcare Conference January 10, M2011 Growth Driven by Consumer Health and Emerging Markets Sales in million; % y-o-y, ( ) Fx & portfolio adj. Consumer Health +4% (+6%) 25% Sales Pharma ±0% (+1%) Adjusted EBITDA* 3,267 3,522 Earnings +8% Adjusted EBIT* 37% 2,270 2,463 +9% 2,258 2, % 63% 1,459 1, % 997 1,059 +6% % HealthCare 12,574m +1% (+2%) 9M10 9M11 9M10 9M11 Price -0.1% Volume 2.5% Fx -1.7% Page 2 J.P. Morgan Healthcare Conference January 10, 2012 Portfolio 0.3% * before special items
4 Major Progress Achieved Pipeline Progress Efficiency Improvement Emerging Markets Consumer Health Key late-stage pipeline assets progressed as planned or better Strong early- and mid-stage pipeline Savings program on track Targeting approx. 430m p.a. Pharma margin improved Double digit sales growth in 9M2011 Expansion of marketing and sales organization Strong growth of key brands 13 consumer brands with annual sales of > 100m each (FY 2010) Page 3 J.P. Morgan Healthcare Conference January 10, 2012 Challenges For Our Healthcare Business Going Forward Pressure on sales / earnings Significant investment requirements Increasing generic competition Healthcare reforms Promising late-stage pharma pipeline Several market introductions Emerging markets growth Consumer Health expansion Outlook 2011 projects below market growth in Pharma Resourcing organic growth Page 4 J.P. Morgan Healthcare Conference January 10, 2012
5 Building Growth Momentum Priority 1 Pharma-pipeline / Launches Opportunity 4 potential blockbuster products to be launched near-term 1 2 Emerging Markets High-single to double-digit growth 3 Consumer Care Positioned for above-market growth 4 Radiology & Interventional² Synergy creation through integration 5 1 Subject to approval of Xarelto, VEGF Trap-Eye, Regorafenib & Alpharadin as expected 2 New unit will combine Diagnostic Imaging (contrast media) and MEDRAD (injection devices) Page 5 J.P. Morgan Healthcare Conference January 10, Promising Late-Stage Pharma Pipeline What it does Status Cardiology Xarelto inhibits blood clot formation launched, filed, phase III Riociguat lowers blood pressure in the lung phase III Nexavar inhibits enzymes important for tumor growth launched, additional indications in phase II/III Oncology Regorafenib inhibits enzymes important for tumor growth CORRECT trial (phase III) in CRC stopped early on success, phase III (GIST) Alpharadin targeted treatment of bone metastases in prostate cancer ALSYMPCA trial (phase III) stopped early on success Eye Diseases VEGF Trap-Eye inhibits formation of new blood vessels 1st indication filed; phase III Page 6 J.P. Morgan Healthcare Conference January 10, 2012
6 Xarelto Novel Direct Factor Xa Inhibitor Large global program involving over 75,000 patients Met or exceeded primary efficacy endpoints in 9 phase III studies: RECORD 1-4; EINSTEIN DVT and EINSTEIN Extension; Rocket AF; ATLAS TIMI 51; MAGELLAN Marketing & regulatory status: Launched in >85 countries (incl. Europe and the US) for VTE prevention following total knee / hip replacement surgery Launched in the US after approval for stroke prevention in patients with atrial fibrillation (SPAF) Launched in Europe after approval for SPAF and DVT treatment ATLAS ACS-TIMI 51 Phase III trial met primary efficacy endpoint and showed significant reduction in mortality (>30%); filed for secondary prevention of ACS in Europe and the US EINSTEIN PE phase III program ongoing data expected early 2012 Page 7 J.P. Morgan Healthcare Conference January 10, 2012 DVT: deep vein thrombosis; VTE: venous thromboembolism ACS: acute coronary syndrome Xarelto Above 2bn Commercial Opportunity 1 UFH VKA DTI % % % Anticoagulants sales MAT 9/2011 Other % ~$9.2bn LMWHs: low molecular weight heparins UFH: unfractionated heparins VKA: Vitamin K antagonists DTI: direct thrombin inhibitors (incl. Pradaxa) Other antithrombotics (incl. Xarelto) Page 8 J.P. Morgan Healthcare Conference January 10, % LMWH Anticoagulants estimated treatment days in 2010 VTE treatment Other primary prevention ~400 ~100 VTE prevention after orthopedic surgery Post ACS/MI ~200 ~350 ~3,100 million ~2,100 Stroke prevention in AF AF: atrial fibrillation ACS: acute coronary syndrome VTE: venous thromboembolism MI: myocardial infarction Source: IMS MIDAS, GERS, FARMINFORM for sales; Bayer estimates for patient treatment days in main markets 1 Subject to approval
7 VEGF Trap-Eye Fusion Protein To Combat Eye Diseases In-licensed from Regeneron Bayer has exclusive marketing rights ex-us Met primary efficacy endpoint in 4 phase III studies (VIEW I & II, Copernicus & Galileo) Submitted for marketing approval in more than 10 countries incl. EU and Japan for wet age related macular degeneration (AMD) 1 Filing for central retinal vein occlusion (CRVO) planned for 2012 Additional studies in diabetic macular edema (DME) and myopic choroidal neovascularization (CNV) ongoing Start of SIGHT-Study in China phase III for wet AMD 1 Regeneron Pharmaceuticals holds US rights, FDA approval November 2011 Page 9 J.P. Morgan Healthcare Conference January 10, 2012 Alpharadin New Opportunity to Treat Bone Metastases Alpha-pharmaceutical (based on Radium-223, delivering highly energetic, short ranging radiation) - in-licensed from Algeta Radium as natural bone seeker targeting bone metastases ALSYMPCA (phase III) in patients with bone metastases in prostate cancer (CRPC) stopped early - Alpharadin demonstrated 44% improvement in overall survival Filing targeted mid 2012 Fast track status granted by FDA Tumor cells Newly formed bone Bone metastases Radium-223 deposition Radium-223: highly localized tumor cell killing Page 10 J.P. Morgan Healthcare Conference January 10, 2012 CRPC: symptomatic castration-resistant prostate cancer
8 Regorafenib New Treatment Option in Cancer Oral multi-kinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases Currently studied in late-stage clinical trials in metastatic colorectal cancer (mcrc) and gastrointestinal stromal tumors (GIST) CORRECT phase III trial in mcrc* stopped early on success (Oct 11) Study met its primary endpoint of significantly improving overall survival Full data to be presented at ASCO-GI congress in January 2012 Submission for marketing authorization in mcrc planned for 2012 Phase III program in GIST ongoing, expect results early 2012 FDA granted orphan drug (GIST) and Fast Track (GIST & mcrc) designation * for patients whose disease has progressed after approved standard therapies Page 11 J.P. Morgan Healthcare Conference January 10, 2012 Four Potential Blockbuster Products Expected to be Launched Near-term Project Indications Peak sales potential* Xarelto SPAF, other anticoagulation > 2bn VEGF Trap-Eye wet AMD, DME, CRVO, myopic CNV 1bn Alpharadin Bone metastases in cancers 1bn Regorafenib mcrc, GIST, other cancers 1bn * Subject to approval as expected Page 12 J.P. Morgan Healthcare Conference January 10, 2012
9 Strong Development Pipeline New molecular entities (NME) Life cycle management (LCM) Status as of December 2011 Table provides a selection of major pharma pipeline projects Page 13 J.P. Morgan Healthcare Conference January 10, Business Momentum in Emerging Markets Sales in million; % y-o-y Fx adjusted 9M2011 HealthCare Sales Emerging Economies USA -3% 25% 32% Emerging Economies¹ +11% +16% +8% 22% 14% ~1,260 ~1,350 +5% +13% ~730 32% ~650 Western Europe -1% Others² +4% HealthCare 12,574m Emerging Asia³ Latin America Eastern Europe Africa & Middle East ¹ Emerging economies include: Latin America, Asia w/o Japan, Australia, New Zealand, Africa and Middle East incl. Turkey, Eastern Europe ² Others = Japan, Australia, New Zealand, Canada ³ Emerging Asia = Asia without Japan, Australia, New Zealand Page 14 J.P. Morgan Healthcare Conference January 10, 2012
10 Bayer is One of The Leading International HealthCare Companies in China Sales in million; % y-o-y Fx adjusted HealthCare 9M m +24% y-o-y (Fx-adj.)* Strong growth Driven by Pharmaceuticals ~1,000 sales representatives added in 2011 Significant investment commitment Approx. 6,200 employees (Sept. 30, 2011) Top products growth in 9M2011* Aspirin Adalat Avelox Nexavar Glucobay +49% +30% +24% +24% +23% 100m over 5 years to set-up a global R&D center in China Beijing manufacturing site expansion (~ 45m through 2015) Partnership with Tsinghua University (joint drug discovery, student support) * People s Republic of China Page 15 J.P. Morgan Healthcare Conference January 10, 2012 Targeting Sales of ~ 2.5bn in Greater China by 2015 Sales of BHC in Greater China in billion ~ 2.5 IMS predicts annual pharma market growth in China of ~17% ( ) 0.9 Market growth drivers: Increasing government healthcare funding Growing and ageing population Higher prevalence in chronic and lifestyle-related diseases Increasing affordability of modern medicines e Expanding market reach through business regionalization Global R&D center and global headquarters for Primary Care in China Page 16 J.P. Morgan Healthcare Conference January 10, 2012
11 3. Consumer Care A Highly Attractive Market Sales Consumer Care in million; % y-o-y Fx and portf. adjusted 3,020 3,080 3,371 +8% Highlights Global #2 2,355 2,531 2,634 2,588 Track record of performance Some of the world s most recognized brands 1,336 Acquired Roche OTC, Citracal, Sagmel and Topsun Significant organic as well as inorganic growth opportunities M2011 Page 17 J.P. Morgan Healthcare Conference January 10, 2012 Strong Consumer Care Brands Sales in million; % y-o-y Fx adjusted Brand 9M2011 Sales y-o-y Growth 324* +10% % % % % % * Only Aspirin CC sales, excluding Rx Aspirin Cardio Page 18 J.P. Morgan Healthcare Conference January 10, 2012
12 4. Radiology & Interventional Combining Medrad and Diagnostic Imaging Contrast Media Highlights Medrad: Fluid Injection Systems Endovascular Devices Clear #1 Active in fluid injection systems for contrast media and endovascular devices Business strengthened around strategic core through adjacent acquisitions of Possis (thrombectomy) and Pathway (mechanical atherectomy) Diagnostic Imaging: Clear market leader in contrast media Synergy creation through integration underway Page 19 J.P. Morgan Healthcare Conference January 10, 2012 Summary Committed to building growth momentum in HealthCare Four potential blockbuster products expected to be launched near-term Strong development pipeline Excellent position in emerging markets Consumer Health businesses well positioned for attractive growth Page 20 J.P. Morgan Healthcare Conference January 10, 2012
13 Reporting Events and AGM Date Event Publication Tuesday, February 28, 2012 Investor Conference Call 2011 Annual Report Tuesday/Wednesday, March 13 & 14, 2012 Thursday, April 26, 2012 Friday, April 27, 2012 Tuesday, July 31, 2012 Tuesday, October 30, 2012 Meet Management, Leverkusen Investor Conference Call Annual General Meeting Investor Conference Call Investor Conference Call Investor Conference 1 st Quarter 2012 Results Stockholders Newsletter 2 nd Quarter 2012 Results Stockholders Newsletter 3 rd Quarter 2012 Results Stockholders Newsletter Page 21 J.P. Morgan Healthcare Conference January 10, 2012 Investor Relations Contacts Dr. Alexander Rosar Head of Investor Relations Phone: alexander.rosar@bayer.com Dr. Jürgen Beunink Phone: juergen.beunink@bayer.com Peter Dahlhoff Phone: peter.dahlhoff@bayer.com Fabian Klingen Phone: fabian.klingen@bayer.com Ute Menke Phone: ute.menke@bayer.com Judith Nestmann Phone: judith.nestmann@bayer.com Dr. Olaf Weber Phone: olaf.weber@bayer.com Page 22 J.P. Morgan Healthcare Conference January 10, 2012
Building Growth Momentum in HealthCare
Building Growth Momentum in HealthCare Marijn Dekkers, CEO September 20, 2011 UBS Life Science Conference Disclaimer This presentation may contain forward-looking statements based on current assumptions
More informationUniCredit German Investment Conference. Building growth momentum. Dr. Alexander Rosar Head of Investor Relations. 2011, September 29, Munich
UniCredit German Investment Conference Building growth momentum Dr. Alexander Rosar Head of Investor Relations 2011, September 29, Munich Disclaimer This presentation may contain forward-looking statements
More informationDisclaimer. Building growth momentum. Roadshow The Netherlands / Brussels
Building growth momentum Roadshow The Netherlands / Brussels October 4-5, 2011 Disclaimer This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer
More informationUBS Global Life Sciences Conference Dr. Marijn Dekkers, CEO Bayer AG
UBS Global Life Sciences Conference Dr. Marijn Dekkers, CEO Bayer AG September 20, 2012 Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and
More informationInvestor Presentation
Das Bild kann zurzeit nicht angezeigt werden. Das Bild kann zurzeit nicht angezeigt werden. Das Bild kann zurzeit nicht angezeigt werden. Roadshow Frankfurt Investor Presentation Dr. Marijn Dekkers CEO
More informationBuilding a world class innovation company
Das Bild kann zurzeit nicht angezeigt werden. Das Bild kann zurzeit nicht angezeigt werden. Das Bild kann zurzeit nicht angezeigt werden. Cheuvreux German Corporate Conference Building a world class innovation
More informationInvestor Handout Q April 2012 I Leverkusen
Investor Handout Q1 2012 April 2012 I Leverkusen Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup
More informationInvestor Handout. Roadshow California
Investor Handout Roadshow California July 2012 Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup
More informationInvestor Handout. Roadshow Scandinavia
Investor Handout Roadshow Scandinavia June 15/16, 2011 Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group
More informationInvestor Handout Roadshow London Marijn Dekkers, CEO
Investor Handout Roadshow London Marijn Dekkers, CEO May 25-26, 2011 Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and forecasts made by
More informationInvestor Handout Q2 2013
Investor Handout Q2 2013 August 2013 This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown
More informationNon-Deal Debt Roadshow
Science For A Better Life Non-Deal Debt Roadshow Johannes M. Dietsch, Finance Director December 2007 Bayer Non-Deal Debt Roadshow December 2007 Disclaimer This presentation contains forward-looking statements
More informationQ Analyst and Investor Briefing July 31, 2012
Q2 212 Analyst and Investor Briefing July 31, 212 Bayer raises guidance for the full year Strong business performance in the second quarter of 212 Record sales 1.2 billion (+5.% Fx and portfolio adjusted)
More informationInvestor Conference Call FY/Q Results
Science For A Better Life Investor Conference Call FY/Q4 Results Werner Wenning, CEO February 26 2010 FY/Q4 Investor Conference Call Werner Wenning Disclaimer This presentation may contain forward-looking
More informationQ Analyst and Investor Briefing April 29, 2009
Q1 2009 Analyst and Investor Briefing April 29, 2009 Sales declined by 7.5% to 7,895m (Q1 08: 8,536m); Volume -9.4%, price -0.3%, currency +1.9%, portfolio +0.3%. Portfolio and Fx adj. sales dropped by
More informationQ Analyst and Investor Briefing March 3, 2009
Q4 2008 Analyst and Investor Briefing March 3, 2009 Sales declined by 1.5% to 7,923m (Q4 07: 8,040m); Volume -5.7%, price +1.7%, currency +2.0%, portfolio +0.6%. Portfolio and Fx adj. sales dropped by
More informationQ Analyst and Investor Briefing October 27, 2009
Q3 2009 Analyst and Investor Briefing October 27, 2009 Sales declined by 7.0% to 7,392m (Q3 08: 7,948m); volume -2.8%, price -4.4%, currency +0.6%, portfolio -0.4%. Portfolio and Fx adj. sales dropped
More informationQ Analyst and Investor Briefing July 28, 2011
Q2 211 Analyst and Investor Briefing July 28, 211 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Group sales at 9,252 million, up 5.4% (portfolio and currency adjusted) Price
More informationInvestor Conference Call
Investor Conference Call Q3 2014 Results October 30, 2014 / Marijn Dekkers, CEO Page 1 Q3 2014 Investor Conference Call Marijn Dekkers Disclaimer This presentation may contain forward-looking statements
More informationQ Analyst and Investor Briefing February 26, 2010
Q4 2009 Analyst and Investor Briefing February 26, 2010 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Sales declined by 0.6% to 7,872m (Q4 08: 7,923m); volume 8.2%, price
More informationInvestor News. Bayer: strong business momentum continues and portfolio transformation underway. Fiscal 2014:
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Fiscal 2014: Bayer: strong business momentum continues and portfolio transformation underway Group portfolio to
More informationManagement Board Chairman Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG:
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Management Board Chairman Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG: Bayer has great potential
More informationInvestor Handout Q3 2014
Investor Handout Q3 2014 November 2014 This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and
More informationInvestor Conference. London, August 6, First Half 2003 Results
Investor Conference London, August 6, 23 First Half 23 Results Safe Harbor This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management.
More informationInvestor News. Another record year for Bayer. Fiscal 2015:
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Fiscal 2015: Another record year for Bayer Focus on the Life Sciences following the successful stock market flotation
More informationCautionary Statements Regarding Forward-Looking Information
Investor Handout December 2016 Cautionary Statements Regarding Forward-Looking Information Certain statements contained in this communication may constitute forward-looking statements. Actual results could
More informationScience For A Better Life. UniCredit German Investment Conference. Dr. Alexander Rosar Head of Investor Relations September
Science For A Better Life UniCredit German Investment Conference Dr. Alexander Rosar Head of Investor Relations September 24 2008 V Sept08 Me Important Information This presentation may contain forward-looking
More informationDr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG:
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG: Bayer has outstanding perspectives as a pure
More informationBayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement Leverkusen, February 11,
More informationQ Analyst and Investor Briefing October 28, 2010
Q3 21 Analyst and Investor Briefing October 28, 21 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Further growth in Group sales and underlying EBITDA mainly driven by business
More informationInvestor Conference Call
Investor Conference Call FY/Q4 2015 Results February 25, 2016 / Marijn Dekkers, CEO Page 1 Q4/FY 2015 Investor Conference Call Marijn Dekkers Disclaimer This presentation may contain forward-looking statements
More informationScience For A Better Life. Investor Handout Q V Oct 08
Science For A Better Life Investor Handout Q3 2008 V Oct 08 Important Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group
More informationQ Analyst and Investor Briefing February 28, 2018
Q4 217 Analyst and Investor Briefing February 28, 218 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Q4 217: Sales at 8,596 million (+2.7% Fx & portf. adj.) EBITDA before special
More informationof 5 01/08/ :58
July 31, 2012 Strong business performance in the second quarter of 2012: Sales increased by 10.0 percent to a record EUR 10,177 million / CropScience and HealthCare sustained strong momentum, MaterialScience
More informationInvestor Conference Call
Investor Conference Call FY/Q4 2014 Results February 26, 2015 / Marijn Dekkers, CEO Disclaimer This presentation may contain forward-looking statements based on current assumptions and forecasts made by
More informationBayer boosts third-quarter earnings: operating result doubled
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Fall Financial News Conference of Bayer AG Bayer boosts third-quarter earnings: operating result doubled Third-quarter
More informationThird Quarter Results 2005
Science For A Better Life Company Presentation Third Quarter Results 25 Forward Looking Statements This presentation contains forward-looking statements based on current assumptions and forecasts made
More informationNews Release. Bayer: operating performance on track. Financial News Conference on fiscal 2010:
News Release Bayer AG Communications 51368 Leverkusen Germany Tel. +49 214 30-1 www.press.bayer.com Financial News Conference on fiscal 2010: Bayer: operating performance on track Group targets achieved
More informationNews Release. Bayer: sales and EBIT at record levels. Financial and innovation targets for 2011 achieved
News Release Bayer AG Communications 51368 Leverkusen Germany Tel. +49 214 30-1 www.press.bayer.com Financial and innovation targets for 2011 achieved Bayer: sales and EBIT at record levels Sales increase
More informationBayer: Operational business held back by currency effects Major progress with Monsanto acquisition
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com First quarter of 2018 Bayer: Operational business held back by currency effects Major progress with Monsanto acquisition
More informationSpring Investor Conference 2003
Spring Investor Conference 2003 Rolf Classon, Bayer HealthCare Safe Harbor This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management.
More informationDr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG:
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG: Innovation is our future 2015 was a very successful
More informationP o r t o l A 2013 Ann Port 2013 Inno ol vative SCIenCe. PaA tient Fo CuSed. u A l r E P o r t
PortolA nl 2013 InnovatIve SCIenCe. lc PatIent FoCuSed. tnov patients Our VariOus academic collaborators VariOus portola employees our company We are POrTOla PHarMaCeUTICalS. Our mission is to build a
More informationStockholders Newsletter
k Cover Picture Stockholders Newsletter F i n a n c i a l r e p o r t a s o f S e p t e m b e r 3 0, 2 0 1 1 After a good third quarter: Bayer confirms Group outlook Contents Interim Group management Report
More informationBayer: Good performance in a challenging environment, Group outlook confirmed
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Third quarter of 2018 Bayer: Good performance in a challenging environment, Group outlook confirmed Group sales
More informationInvestor Conference Call FY/Q Results
For A Better Life Investor Conference Call FY/Q4 2006 Results Werner Wenning, CEO March 15 2007 Disclaimer This presentation contains forward-looking statements based on current assumptions and forecasts
More informationInterim Report. Third Quarter of Bayer posts strong earnings growth
Interim Report Third of Bayer posts strong earnings growth 2 Bayer Interim Report Key Data Bayer Group Key Data Change Change Full Year million million % million million % million Sales 9,967 11,036 +
More informationCautionary Statements Regarding Forward-Looking Information
Investor Handout November 2016 Cautionary Statements Regarding Forward-Looking Information Certain statements contained in this communication may constitute forward-looking statements. Actual results could
More informationCelgene Reports First Quarter 2009 Operating and Financial Results. SUMMIT, N.J.--(BUSINESS WIRE)--Apr. 30, Celgene Corporation (NASDAQ: CELG):
Celgene Reports First Quarter 2009 Operating and Financial Results SUMMIT, N.J.--(BUSINESS WIRE)--Apr. 30, 2009-- Celgene Corporation (NASDAQ: CELG): REVLIMID Continues Gains in Multiple Myeloma Both in
More informationStockholders Newsletter Financial Report as of September 30, 2013
Stockholders Newsletter Financial Report as of September 30, k Cover Picture Third quarter of : Bayer continues positive business momentum Contents Interim Group management Report as of September 30,...4
More informationStockholders Newsletter
Stockholders Newsletter Financial Report as of September 30, Bayer continues on path of growth in third quarter 8 For direct access to a chapter, simply click on its name. R Bayer Group Key Data 2 Interim
More informationFirst Quarter of 2018
Q Interim Report First Quarter of 208 Bayer Interim Report as of March 3, 208 Key Data 2 Bayer Group Key Data Full Year million Q 207 Q 208 Change % 207 Sales 9,680 9,38 5.6 35,05 Change (adjusted for
More informationInterim Report. First Quarter of Strong start to the year for Bayer
Interim Report First Quarter of Strong start to the year for Bayer 2 Bayer Interim Report Key Data Bayer Group Key Data Change Full Year million million % million Sales 10,555 12,117 + 14.8 42,239 Change
More informationBayer increases sales and earnings in the second quarter
News Release Bayer AG Communications 51368 Leverkusen Germany Tel. +49 214 30-1 www.press.bayer.com MaterialScience leaves the crisis behind Bayer increases sales and earnings in the second quarter Sales
More informationCombined Management Report of the Bayer Group and Bayer AG as of December 31, (Extract from the Annual Report 2012)
Combined Management Report of the Bayer Group and Bayer AG as of December 31, (Extract from the Annual Report ) 52 Bayer Annual Report Combined Management Report of the Bayer Group and Bayer AG as of December
More informationSunesis Pharmaceuticals Reports Second Quarter 2014 Financial Results and Recent Highlights. VALOR Trial Reaches Prespecified Events for Unblinding
Sunesis Pharmaceuticals Reports Second Quarter 2014 Financial Results and Recent Highlights August 5, 2014 7:00 AM ET VALOR Trial Reaches Prespecified Events for Unblinding Sunesis to Host Conference Call
More informationQ Analyst and Investor Briefing September 5, 2018
Q2 218 Analyst and Investor Briefing September 5, 218 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer completes biggest acquisition in its history Monsanto business included
More informationAcquisition of Merck s Consumer Care Business & Pharma sgc Cooperation
Acquisition of Merck s Consumer Care Business & Pharma sgc Cooperation Investor Conference Call May 6, 2014 / Marijn Dekkers, CEO Page 1 Investor Conference Call Marijn Dekkers May 6, 2014 Disclaimer This
More informationFull Year million Q Q Change % 2016
Interim Report First Quarter of 207 Bayer Interim Report as of March 3, 207 Key Data 2 Bayer Group Key Data Full Year million Q 206 Q 207 Change % 206 Sales,854 3,244 +.7 46,769 Change (adjusted for currency
More informationNews Release. Bayer shows strong performance Acquisition of Monsanto agreed. Third quarter of 2016:
News Release Bayer AG Corporate Brand, Communications & Government Relations 51368 Leverkusen Germany Phone +49 214 30-0 www.news.bayer.com Third quarter of 2016: Bayer shows strong performance Acquisition
More informationA N N U A L R E P O R T
ANNUAL REPORT 2005 OVERVIEW The Medicines Company meets the demands of the world s most advanced medical practitioners by developing products that improve acute hospital care. The Company s acute care
More informationBayer AG successfully placed new shares at Euro per share
Ad-hoc-Report according to 15 WpHG Investor Relations 51368 Leverkusen www.investor.bayer.com Not for distribution in or into the United States of America, Australia, Canada, United Kingdom or Japan successfully
More information2008 Fourth Quarter Financial Results Year-Over-Year:
Celgene Reports Record Fourth Quarter and Full Year 2008 Product Sales and Operating Profits SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG): REVLIMID #1 Therapy in Multiple Myeloma
More information1 sur 9 26/07/ :19
1 sur 9 26/07/2012 13:19 Print Page Close Window Press Releases Celgene Reports Second Quarter 2012 Operating and Financial Results Total Revenue of $1.37 Billion and Net Product Sales of $1.34 Billion,
More informationCredit Suisse Healthcare Conference
Credit Suisse Healthcare Conference Murdo Gordon Head, Worldwide Markets November 10, 2015 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects
More informationFull Year million Q Q Change % 9M M 2017 Change % 2016
Interim Report Third Quarter of 207 Bayer Interim Report as of September 30, 207 Key Data 2 Bayer Group Key Data Full Year million Q3 206 Q3 207 Change % 9M 206 9M 207 Change % 206 Sales 8,258 8,025 2.8
More informationLigand to Acquire Metabasis for Cash and Contingent Value Rights
October 27, 2009 Ligand to Acquire Metabasis for Cash and Contingent Value Rights Ligand to Gain Fully Funded Partnership with Roche for Hepatitis and Promising Development-Stage Programs SAN DIEGO-- Ligand
More informationLucentis(Ranibizumab)
Policy Number LUC01112012RP Approved By UnitedHealthcare Medicare Committee Current Approval Date 06/11/2014 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable to UnitedHealthcare
More informationFortress Biotech Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
Fortress Biotech Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights New York, NY November 9, 2018 Fortress Biotech, Inc. (NASDAQ: FBIO) ( Fortress ), a biopharmaceutical company
More informationSeptember 18, 2014 / Marijn Dekkers, CEO
Transforming Bayer into a Pure Life Company - Exit of Material September 18, 2014 / Marijn Dekkers, CEO Page 1 Investor Conference Call Marijn Dekkers September 18, 2014 Disclaimer This presentation may
More informationEllex Medical Lasers. Investor Presentation for six months ended 31 December (prepared 17 March 2014) Tom Spurling, CEO
Ellex Medical Lasers Investor Presentation for six months ended 31 December 2013 (prepared 17 March 2014) Tom Spurling, CEO Ellex develops, manufactures and markets lasers, ophthalmic implants and diagnostic
More informationInterim Report Second Quarter of 2017
Interim Report Second Quarter of 207 Bayer Interim Report as of June 30, 207 Key Data 2 Bayer Group Key Data million Q2 206 Q2 207 Change % H 206 H 207 Change % Full Year 206 Sales,833 2,93 + 3.0 23,687
More informationStockholders Newsletter Financial Report as of March 31, 2013
k Cover Picture Stockholders Newsletter Financial Report as of March 31, First quarter of : Bayer: Life Sciences off to a good start in anniversary year Contents Interim Group management Report as of March
More informationBayer creates a provision in the amount of 275 million euros for civil antitrust actions
Ad-hoc-Report according to 15 WpHG Investor Relations 51368 Leverkusen www.investor.bayer.com Bayer creates a provision in the amount of 275 million euros for civil antitrust actions Leverkusen, December
More informationFY 2008 First Quarter Results. August 4, 2008 Santen Pharmaceutical Co., Ltd
FY 2008 First Quarter Results August 4, 2008 Santen Pharmaceutical Co., Ltd 1 FY 2008 First Quarter Consolidated Financial Results Chief Financial Officer Yoshihiro Noutsuka Forward-looking statements:
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Investor Presentation May 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive
More information1. The Board of Directors' report on the Company's activities in the past year.
1 AGENDA 1. The Board of Directors' report on the Company's activities in the past year. 2. Presentation of the Annual Report for adoption. 3. A proposal from the Board of Directors regarding the application
More informationForward-Looking Statements. Consolidated Financial Results for the 3rd Quarter of Fiscal Year François-Xavier Roger Chief Financial Officer
Consolidated Financial Results for the 3rd Quarter of Fiscal Year 2014 François-Xavier Roger Chief Financial Officer February 5, 2015 Forward-Looking Statements This presentation contains forward-looking
More informationFor personal use only
Sirtex Medical Limited 2017 Annual General Meeting Sydney, Australia 24 October 2017 SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd 1For personal use only 2017 Annual General Meeting
More information1 sur 8 25/07/ :40
1 sur 8 25/07/2013 11:40 Print Page Close Window Press Releases Celgene Reports Second Quarter 2013 Operating and Financial Results Net Product Sales of $1.56 Billion, Increased 17 Percent Y/Y Adjusted
More informationJefferies 2014 Global Healthcare Conference
Jefferies 2014 Global Healthcare Conference June 4 th, 2014 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the federal securities laws. This includes
More informationVIFOR PHARMA IR PRESENTATION
PRESENTATION VIFOR PHARMA IR PRESENTATION May 2018 VIFOR PHARMA VISION Global Leader in Iron Deficiency, Nephrology and Cardio-Renal Therapies. May 2018 2 AGENDA 1 Experienced leadership team 2 3 Proven
More informationAVEO Reports First Quarter 2018 Financial Results and Provides Business Update
AVEO Reports First Quarter 2018 Financial Results and Provides Business Update CAMBRIDGE, Mass. May 8, 2018 AVEO Oncology (NASDAQ: AVEO) today reported financial results for the first quarter ended March
More informationQuarterly Cashflow Report
Quarterly Cashflow Report Melbourne, Australia; 17 July 2018: Starpharma (ASX: SPL, OTCQX: SPHRY) today released its Appendix 4C Quarterly Cashflow Report for the period ended 30 June 2018. Starpharma
More informationAbbott Reports First-Quarter 2019 Results
News Release Abbott Reports First-Quarter 2019 Results Sales and EPS growth exceed guidance; projects strong full-year outlook Long-term growth drivers including FreeStyle Libre, MitraClip and Alinity
More informationIpsen FY 2018 Results. February 14, 2019
Ipsen FY 2018 Results February 14, 2019 Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates
More informationPieris Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 10, 2018 Pieris Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, MAY 10, 2018 AT 8:00 AM EDT BOSTON,
More informationFinancial Targets through 2022: Focus on Value Creation
Financial Targets through 2022: Focus on Value Creation /////////// Capital Markets Day London, December 5, 208 Wolfgang Nickl CFO Bayer AG Disclaimer Cautionary Statements Regarding Forward-Looking Information
More informationLupin Ltd. Investor Presentation Q2 FY Oct 28, 2014
Lupin Ltd. Investor Presentation Q2 FY2014-15 Oct 28, 2014 Safe harbor statement Materials and information provided during this presentation may contain forward-looking statements. These statements are
More informationInvestor Conference Call
Investor Conference Call Q3 2017 Results October 26, 2017 / Werner Baumann, CEO Cautionary Statements Regarding Forward- Looking Information Certain statements contained in this communication may constitute
More informationClavis Pharma ASA. First Quarter Report 2008
Clavis Pharma ASA First Quarter Report 2008 Clavis Pharma uses its proprietary Lipid Vector Technology (LVT) to develop new and superior pharmaceuticals by improving already established drugs. The Company
More informationPrescription medicines trends: an overview and perspective on two therapy areas
Prescription medicines trends: an overview and perspective on two therapy areas Sarah Rickwood, Vice President, IQVIA Copyright 217 IQVIA. All rights reserved. We will discuss four issues Global prescription
More informationInterim Report, First Quarter 2014
Interim Report, First Quarter 2014 CORTENDO REPORTS RESULTS AND ACTIVITIES FOR THE FIRST QUARTER 2014 FIRST AND POST QUARTER HIGHLIGHTS Continued progress on the start-up of NormoCort Phase 3 trial While
More informationCONTACT: Chief Financial. Officer UPDATE. in the first quarter of Cushing s syndrome. quarter of The company raised its. quarter of.
CONTACT: Charles Robb Chief Financial Officer Corcept Therapeutics 650-688-8783 crobb@corcept.com www.corcept.com CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER 2017 FINANCIAL RESULTS, RAISES 2017 REVENUE
More informationStockholders Newsletter
Stockholders Newsletter Half-Year Financial Report as of June 30, Bayer continues on a path of growth 8 For direct access to a chapter, simply click on its name. Interim Group Management Report as of June
More informationAerie Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
Aerie Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update November 6, 2018 Conference Call and Webcast Today, November 6 th, at 5:00 p.m. ET DURHAM, N.C.--(BUSINESS
More informationRegeneron Reports Third Quarter 2018 Financial and Operating Results
Regeneron Reports Third Quarter 2018 Financial and Operating Results November 6, 2018 TARRYTOWN, N.Y., Nov. 6, 2018 /PRNewswire/ -- Third quarter 2018 EYLEA (aflibercept) Injection U.S. net sales increased
More informationEMISPHERE TECHNOLOGIES INC
EMISPHERE TECHNOLOGIES INC FORM 10-K405 (Annual Report (Regulation S-K, item 405)) Filed 04/01/02 for the Period Ending 12/31/01 Address 240 CEDAR KNOLLS RD. SUITE 200 CEDAR KNOLLS, NJ 07927 Telephone
More informationUBS Australasia conference. Ian Kadish (MD & CEO) 13 November 20
UBS Australasia conference Ian Kadish (MD & CEO) 13 November 20 Integral Diagnostics is a leading Diagnostic Imaging business in Victoria, Queensland and Western Australia Long history in each respective
More information1. The Board of Directors' report on the Company's activities in the past year.
AGENDA 1. The Board of Directors' report on the Company's activities in the past year. 2. Presentation of the Annual Report for adoption. 3. A proposal from the Board of Directors regarding the application
More information